84 related articles for article (PubMed ID: 16273555)
1. Induction of murine leukemia and lymphoma by dominant negative retinoic acid receptor alpha.
Wang YA; Shen K; Ishida Y; Wang Y; Kakizuka A; Brooks SC
Mol Carcinog; 2005 Dec; 44(4):252-61. PubMed ID: 16273555
[TBL] [Abstract][Full Text] [Related]
2. The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.
Testa U; Grignani F; Samoggia P; Zanetti C; Riccioni R; Lo Coco F; Diverio D; Felli N; Passerini CG; Grell M; Pelicci PG; Peschle C
J Clin Invest; 1998 May; 101(10):2278-89. PubMed ID: 9593784
[TBL] [Abstract][Full Text] [Related]
3. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
[TBL] [Abstract][Full Text] [Related]
4. Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia.
Chim CS; Wong SY; Pang A; Chu P; Lau JS; Wong KF; Kwong YL
Leukemia; 2005 Dec; 19(12):2241-6. PubMed ID: 16239915
[TBL] [Abstract][Full Text] [Related]
5. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia.
Pandolfi PP
Hum Mol Genet; 2001 Apr; 10(7):769-75. PubMed ID: 11257111
[TBL] [Abstract][Full Text] [Related]
6. The theory of APL.
Piazza F; Gurrieri C; Pandolfi PP
Oncogene; 2001 Oct; 20(49):7216-22. PubMed ID: 11704849
[TBL] [Abstract][Full Text] [Related]
7. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
Duprez E; Lillehaug JR; Gaub MP; Lanotte M
Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
[TBL] [Abstract][Full Text] [Related]
8. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
[TBL] [Abstract][Full Text] [Related]
9. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
11. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil elastase is important for PML-retinoic acid receptor alpha activities in early myeloid cells.
Lane AA; Ley TJ
Mol Cell Biol; 2005 Jan; 25(1):23-33. PubMed ID: 15601827
[TBL] [Abstract][Full Text] [Related]
13. Translocations of the RARalpha gene in acute promyelocytic leukemia.
Zelent A; Guidez F; Melnick A; Waxman S; Licht JD
Oncogene; 2001 Oct; 20(49):7186-203. PubMed ID: 11704847
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid.
Mologni L; Marchesi E; Nielsen PE; Gambacorti-Passerini C
Cancer Res; 2001 Jul; 61(14):5468-73. PubMed ID: 11454693
[TBL] [Abstract][Full Text] [Related]
16. Dominant negative retinoic acid receptor initiates tumor formation in mice.
Kupumbati TS; Cattoretti G; Marzan C; Farias EF; Taneja R; Mira-y-Lopez R
Mol Cancer; 2006 Mar; 5():12. PubMed ID: 16563162
[TBL] [Abstract][Full Text] [Related]
17. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
[TBL] [Abstract][Full Text] [Related]
18. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia.
Sternsdorf T; Phan VT; Maunakea ML; Ocampo CB; Sohal J; Silletto A; Galimi F; Le Beau MM; Evans RM; Kogan SC
Cancer Cell; 2006 Feb; 9(2):81-94. PubMed ID: 16473276
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid receptor alpha (RAralpha) Mutations in Human Leukemia.
Parrado A; Chomienne C; Padua RA
Leuk Lymphoma; 2000 Oct; 39(3-4):271-82. PubMed ID: 11342307
[TBL] [Abstract][Full Text] [Related]
20. Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells.
Ikeda T; Kimura F; Nakata Y; Sato K; Ogura K; Motoyoshi K; Sporn M; Kufe D
Cell Death Differ; 2005 May; 12(5):523-31. PubMed ID: 15746941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
